Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
15.03
-0.06 (-0.40%)
At close: Aug 13, 2026, 4:00 PM EDT
15.09
+0.06 (0.40%)
Pre-market: Aug 14, 2026, 4:01 AM EDT
Generate Biomedicines Revenue
Generate Biomedicines had revenue of $6.31M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $26.48M. In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$26.48M
Revenue Growth
+55.89%
P/S Ratio
72.84
Revenue / Employee
$84,881
Employees
312
Market Cap
1.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GENB News
- 7 days ago - Generate Biomedicines reports Q2 EPS (52c), consensus (49c) - TheFly
- 7 days ago - Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Generate Biomedicines Quarterly report: Q2 2026 - Filings
- 7 days ago - Generate Biomedicines Earnings release: Q2 2026 - Filings
- 4 weeks ago - Generate Biomedicines falls -9.5% - TheFly
- 7 weeks ago - AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts - PRNewsWire
- 2 months ago - Generate Biomedicines Slides: Corporate presentation - Filings
- 2 months ago - Generate Biomedicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts